文献速递中枢神经肿瘤放疗头颈部肿瘤放疗胸部肿瘤放疗

再程放疗的临床证据与报告标准:ESTRO 2025 二十八项研究解读

Clinical evidence and reporting standards in reirradiation: Insights from 28 studies at ESTRO 2025, endorsed by the ESTRO reirradiation focus group.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-12-01

该研究筛选 ESTRO 2025 全部 2962 篇摘要中的 51 项再程放疗研究,最终纳入 28 项报告临床结局的研究,按 ESTRO-EORTC 十项强制报告标准评分。结果显示部分病种疗效鼓舞,但报告质量异质,中位评分仅 5/10,器官功能、累积 OAR 剂量与剂量叠加方法常缺失。

要点

  • 再程放疗报告质量异质,中位仅达 5/10 项 ESTRO-EORTC 强制标准。
  • 器官功能、累积 OAR 剂量和剂量叠加方法最常被遗漏。
  • 仅少数摘要明确区分 type 1 与 type 2 再程放疗。

核心结论

  • ESTRO 2025 摘要集显示现代再程放疗兼具临床潜力与方法学差异,对 ESTRO-EORTC 标准化报告的依从性仍有限。

研究设计与样本

  • 筛选 ESTRO 2025 全部 2962 篇摘要,识别 51 项再程放疗研究,最终纳入 28 项报告至少一项临床结局的研究。
  • 将再程放疗分为 type 1(照射体积有几何重叠)或 type 2(无重叠但 OAR 剂量可能受限),并用 ESTRO-EORTC 十项强制报告标准逐项评分,评分范围 0 至 10。

主要发现

  • 28 项研究涵盖脑、头颈、胸部、盆腔、前列腺、转移及儿童等场景。
  • I 期 DESTROY-1 剂量递增试验局部控制率 > 85%,肺与前列腺队列中位总生存 > 40 个月,≥3 级毒性一般低于 10%。
  • 报告质量异质,中位评分 5/10(IQR 4-7);人口学、处方剂量和技术报告较一致,器官功能、累积 OAR 剂量和剂量叠加方法常被省略。
  • 仅少数摘要明确提供 type 1 或 type 2 再程放疗分类;基线器官功能常缺失,尤其在中枢神经研究中标准化检测很少适用。

关键数值与推荐

  • ESTRO-EORTC 十项强制报告标准涵盖人口学、体能状态、器官功能、复发分类、靶体积、技术与剂量、距首次放疗间隔、累积 OAR 剂量、剂量叠加方法和 CTCAE 毒性。
  • 报告评分范围 0 至 10,本组中位评分 5/10(IQR 4-7)。

临床怎么用

  • 再程放疗临床应用时应按 ESTRO-EORTC 十项强制标准完整报告,尤其补全器官功能、累积 OAR 剂量与剂量叠加方法。
  • 应明确标注再程放疗为 type 1 或 type 2,以便结果可比与 harmonization。

局限性

  • 仅基于 ESTRO 2025 会议摘要,非全文研究,报告内容受摘要篇幅限制。
  • 纳入 28 项研究,样本量与各病种证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reirradiation (reRT) has become an increasingly relevant treatment option across multiple tumor sites, supported by technological advances that improve precision and safety. At the ESTRO 2025 Annual Meeting, 28 clinical studies on reRT were presented. This work provides a structured synthesis of their clinical outcomes and assesses adherence to the ESTRO-EORTC reporting recommendations. MATERIALS AND METHODS: All abstracts presented at ESTRO 2025 (n = 2,962) were screened to identify reRT studies (n = 51). Only studies reporting at least one clinical outcome were retained (n = 28). ReRT was classified as type 1 (with geometric overlap of irradiated volumes) or type 2 (without overlap but with potential OAR dose concerns). Each study was evaluated using the 10 mandatory ESTRO-EORTC reporting criteria, covering demographics, performance status, organ function, recurrence classification, target volume, technique and dose, interval since RT1, cumulative OAR doses, method for dose summation, and CTCAE toxicity. Reporting scores ranged from 0 to 10. RESULTS: The 28 studies encompassed brain, head and neck, thoracic, pelvic, prostate, metastatic, and pediatric settings. Clinical outcomes were encouraging in selected series, with local control > 85 % in the phase I DESTROY-1 dose-escalation trial, median overall survival > 40 months in lung and prostate cohorts, and grade ≥ 3 toxicity generally below 10 %. Reporting quality was heterogeneous: the median score was 5/10 (IQR 4-7). Demographics, prescribed dose, and technique were consistently reported, whereas organ function, cumulative OAR doses, and methods for dose summation were often omitted. Classification as type 1 or type 2 reRT was explicitly provided in only a minority of abstracts. Items such as baseline organ function were often missing, particularly in CNS studies where standardized tests are rarely applicable. CONCLUSION: The ESTRO 2025 abstract set illustrates both the clinical potential and methodological variability of modern reRT. While outcomes are promising across several sites, adherence to standardized reporting remains limited, underscoring the need for consistent implementation of ESTRO-EORTC recommendations to enable comparability and harmonization.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Beddok A, Appelt AL, Corradini S, et al. Clinical evidence and reporting standards in reirradiation: Insights from 28 studies at ESTRO 2025, endorsed by the ESTRO reirradiation focus group. Clin Transl Radiat Oncol. 2025. PMID: 41476914. doi:10.1016/j.ctro.2025.101090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。